KDA Group Partners with AstraZeneca Canada to Advance Genomic Testing for Breast Cancer
I'm PortAI, I can summarize articles.
KDA Group Inc. has partnered with AstraZeneca Canada to promote next-generation sequencing (NGS) diagnostic testing for metastatic breast cancer at Hôpital du Saint-Sacrement. Utilizing KDA's Medherize digital platform, the initiative aims to enhance NGS testing and biomarker-informed care. If successful, it may expand to other healthcare institutions in Québec, Canada, and internationally. This collaboration highlights a significant step in advancing genomic testing for breast cancer.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments